Back to News
Market Impact: 0.35
Zevra Reports Third Quarter 2026 Financial Results and Corporate Update
Source: Nasdaq
Corporate EarningsCompany FundamentalsHealthcare & Biotech
Zevra Therapeutics reported Q3 2026 net revenue of $37.8 million, up 45% from Q3 2025. MIPLYFFA generated $34.0 million of net revenue; the provided article text also cites $0.2 million in additional net revenue but is truncated before further details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.35
Ticker Sentiment
ZVRA0.65
More News
- NextDC shares surge 43% after Goodman, Digital Realty stake purchases
- Asian chip stocks slide as disappointing Qualcomm, Arm earnings weigh
- Snap shares fall over 10% on third-quarter earnings miss
- ‘Seismic’ blue wave triggers the sinking of oil prices, energy stocks, and the chances of power permitting reform
- Softbank’s $5.4 bln takeover of ABB robotics unit blocked by China- FT
- Qualcomm issues disappointing earnings forecast as memory shortage weighs on smartphone sales